Shares of Vitamin Shoppe Inc. (NYSE:VSI) traded down 6.3% on Wednesday . The company traded as low as $26.71 and last traded at $26.71, with a volume of 211,461 shares trading hands. The stock had previously closed at $28.51.

A number of analysts have weighed in on the company. Macquarie reiterated a “neutral” rating and issued a $40.00 price target on shares of Vitamin Shoppe in a research report on Thursday, May 5th. Goldman Sachs Group Inc. cut Vitamin Shoppe to a “hold” rating in a report on Saturday, April 30th. Robert W. Baird restated a “hold” rating on shares of Vitamin Shoppe in a report on Tuesday, April 26th. Wedbush started coverage on Vitamin Shoppe in a report on Wednesday, April 20th. They set an “outperform” rating and a $39.00 target price on the stock. Finally, Jefferies Group restated a “hold” rating and set a $32.00 target price (up previously from $30.00) on shares of Vitamin Shoppe in a report on Friday, May 6th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and one has given a buy rating to the company. Vitamin Shoppe currently has a consensus rating of “Hold” and a consensus price target of $32.82.

The firm’s 50-day moving average is $29.85 and its 200-day moving average is $29.76. The company has a market cap of $621.91 million and a PE ratio of 15.45.

Vitamin Shoppe (NYSE:VSI) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported $0.55 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.59 by $0.04. The business earned $332.70 million during the quarter, compared to analysts’ expectations of $331.58 million. Vitamin Shoppe’s quarterly revenue was up 3.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.57 earnings per share. On average, equities research analysts expect that Vitamin Shoppe Inc. will post $2.17 EPS for the current fiscal year.

In related news, Director Guillermo Marmol acquired 1,000 shares of the company’s stock in a transaction on Tuesday, May 31st. The stock was purchased at an average cost of $30.23 per share, with a total value of $30,230.00. Following the acquisition, the director now directly owns 1,470 shares of the company’s stock, valued at $44,438.10. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

An institutional investor recently raised its position in Vitamin Shoppe stock. Rhumbline Advisers increased its stake in shares of Vitamin Shoppe Inc. (NYSE:VSI) by 4.3% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 45,118 shares of the company’s stock after buying an additional 1,855 shares during the period. Rhumbline Advisers owned about 0.16% of Vitamin Shoppe worth $1,475,000 as of its most recent filing with the SEC.

Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, which includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats; direct, which sells its products directly to consumers through the Internet, primarily at, and manufacturing, which provides custom manufacturing and private labeling of vitamin, mineral and supplement (VMS) products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.